Zim Laboratories

Small Cap 4k Result

₹113.1

-1.25 (-1.09%)

As on 04 December, 2023 | 21:48 BSE: 541400 NSE: ZIMLABISIN: INE518E01015

Zim Laboratories Performance

Day Range

Low 112.50
High 116.40

₹ 113.1

52 Week Range

Low 68.05
High 152.70

₹ 113.1

Open Price115.30
Previous Close114.70
Volume189799

Start SIP in Zim Laboratories

Start SIP

Zim Laboratories Share Price

Over 1 Month -8.94%
Over 3 Month -11.88%
Over 6 Month 5.91%
Over 1 Year 4.69%

Zim Laboratories Key Statistics

P/E Ratio	30.3
PEG Ratio	-1.9
Market Cap Cr	551
Price to Book Ratio	2.8
EPS	5.1
Dividend	0
Relative Strength Index	40.3
Money Flow Index	42.94
MACD Signal	-0.69
Average True Range	3.79

Zim Laboratories Investment Rating

Master Rating:
Zim Laboratories has an operating revenue of Rs. 359.65 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 9% is okay, ROE of 12% is good. The company has a reasonable debt to equity of 12%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 9% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 35 which is a POOR score indicating inconsistency in earnings, a RS Rating of 34 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 64 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Zim Laboratories Financials

Standalone Consolidated

Quarterly P&L
Annual P&L
Balance Sheet
Cash Flow
Ratios
Quarterly P&L
Annual P&L
Balance Sheet
Cash Flow
Ratios

Indicator	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Oper Rev Qtr Cr	85	67	104	100	99	93	104
Operating Expenses Qtr Cr	76	62	89	88	87	81	90
Operating Profit Qtr Cr	9	5	15	13	12	11	14
Depreciation Qtr Cr	4	4	5	4	4	4	4
Interest Qtr Cr	1	2	1	2	1	1	1
Tax Qtr Cr	1	0	3	3	3	2	4
Net Profit Qtr Cr	4	0	7	7	6	6	6

Indicator	Mar 2023	Mar 2022
Total Revenue Annual Cr	403	334
Operating Expenses Annual Cr	345	292
Operating Profit Annual in Cr	51	38
Depreciation Cr	16	15
Interest Annual Cr	6	8
Tax Annual Cr	11	6
Net Profit Annual Cr	25	13

Indicator	Mar 2023	Mar 2022
Cash from Operating Activity Annual Cr	35	47
Cash from Investing Activity Annual Cr	-35	-14
Cash from Financing Annual Activity Cr	1	-33
Net Cash Flow Annual Cr	1	0

Indicator	Mar 2023	Mar 2022
Total ShareHolders Funds Annual Cr	194	170
Fixed Assets Annual Cr	133	115
Total Non Current Assets Annual Cr	156	135
Total Current Assets Annual Cr	179	201
Total Assets Annual Cr	335	335

Indicator	Mar 2023	Mar 2022
Book Value Per Share Annual Rs	40	105
ROE Annual %	13	8
ROCE Annual %	18	15
Total Debt to Total Equity Annual	-	-
EBDIT Annual Margin %	15	13

Indicator	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Oper Rev Qtr Cr	86	67	105	101	99	93	105
Operating Expenses Qtr Cr	77	63	90	88	87	82	90
Operating Profit Qtr Cr	9	5	15	13	12	11	15
Depreciation Qtr Cr	4	4	5	4	4	4	4
Interest Qtr Cr	1	2	1	2	1	1	1
Tax Qtr Cr	1	0	3	3	3	2	4
Net Profit Qtr Cr	4	0	7	7	5	5	7

Indicator	Mar 2023	Mar 2022
Total Revenue Annual Cr	405	338
Operating Expenses Annual Cr	347	292
Operating Profit Annual in Cr	52	41
Depreciation Cr	17	16
Interest Annual Cr	6	8
Tax Annual Cr	11	6
Net Profit Annual Cr	24	15

Indicator	Mar 2023	Mar 2022
Cash from Operating Activity Annual Cr	38	49
Cash from Investing Activity Annual Cr	-36	-15
Cash from Financing Annual Activity Cr	1	-33
Net Cash Flow Annual Cr	2	2

Indicator	Mar 2023	Mar 2022
Total ShareHolders Funds Annual Cr	200	176
Fixed Assets Annual Cr	135	117
Total Non Current Assets Annual Cr	151	129
Total Current Assets Annual Cr	191	212
Total Assets Annual Cr	342	342

Indicator	Mar 2023	Mar 2022
Book Value Per Share Annual Rs	41	108
ROE Annual %	12	8
ROCE Annual %	18	15
Total Debt to Total Equity Annual	-	-
EBDIT Annual Margin %	15	14

Invest in Zim Laboratories

Zim Laboratories Technicals

EMA & SMA

Current Price

₹113.1

-1.25 (-1.09%)

Bullish Moving Average
___
0

Bearish Moving Average
___
0

EMA SMA

20 Day
₹116.81

50 Day
₹118.04

100 Day
₹116.37

200 Day
₹109.07

20 Day
₹117.79

50 Day
₹118.20

100 Day
₹120.92

200 Day
₹105.39

Zim Laboratories Resistance and Support

PIVOT

₹114.34

Resistance
First Resistance	115.67
Second Resistance	117.73
Third Resistance	119.07

RSI	40.30
MFI	42.94
MACD Single Line	-0.69
MACD	-1.12

Support
First Resistance	112.27
Second Resistance	110.93
Third Resistance	108.87

Zim Laboratories Delivery and Volume

Period	NSE + BSE Volume Avg	NSE + BSE Delivery Volume Avg	NSE + BSE Delivery Volume %
Day	198,078	12,130,297	61.24
Week	136,843	7,969,736	58.24
1 Month	189,698	10,581,366	55.78
6 Month	566,800	28,249,290	49.84

Zim Laboratories Result Highlights

Zim Laboratories Synopsis

NSE-Medical-Generic Drugs

Zim Laboratories is involved in the business activities of Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 396.53 Cr. and Equity Capital is Rs. 48.73 Cr. for the Year ended 31/03/2023. Zim Laboratories Ltd. is a Public Limited Listed company incorporated on 14/02/1984 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L99999MH1984PLC032172 and registration number is 032172.

Market Cap	552
Sales	357
Shares in Float	3.26
No of funds	3
Yield

Book Value	2.88
U/D Vol ratio	0.8
LTDebt / Equity	13
Alpha	0.04
Beta	0.91